| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2140470 | Lung Cancer | 2016 | 7 Pages |
Abstract
High MTV and TLG are independently correlated with shorter PFS and OS in advanced EGFR wild-type NSCLC patients treated with second or third-line erlotinib. Metabolic tumor burden is a highly promising clinical tool that may allow better patient selection for palliative treatment in the future.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Anne Winther-Larsen, Joan Fledelius, Boe Sandahl Sorensen, Peter Meldgaard,